vs
NMI Holdings, Inc.（NMIH）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是NMI Holdings, Inc.的1.1倍（$207.3M vs $180.7M），NMI Holdings, Inc.净利率更高（52.1% vs -62.0%，领先114.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 8.5%），NMI Holdings, Inc.自由现金流更多（$412.5M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.5%）
NMI控股是美国头部私人抵押贷款保险服务商，主要为贷款机构提供抵押贷款担保保险产品，降低住房抵押贷款信用风险，服务美国本土住宅市场，助力符合资质的购房者获得购房便利，同时保护放贷机构免受违约损失。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NMIH vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.7M | $207.3M |
| 净利润 | $94.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 67.0% | -54.7% |
| 净利率 | 52.1% | -62.0% |
| 营收同比 | 8.5% | 25.9% |
| 净利润同比 | 9.3% | 3.5% |
| 每股收益（稀释后） | $1.21 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $180.7M | $207.3M | ||
| Q3 25 | $178.7M | $159.9M | ||
| Q2 25 | $173.8M | $166.5M | ||
| Q1 25 | $173.2M | $139.3M | ||
| Q4 24 | $166.5M | $164.6M | ||
| Q3 24 | $166.1M | $139.5M | ||
| Q2 24 | $162.1M | $147.0M | ||
| Q1 24 | $156.3M | $108.8M |
| Q4 25 | $94.2M | $-128.6M | ||
| Q3 25 | $96.0M | $-180.4M | ||
| Q2 25 | $96.2M | $-115.0M | ||
| Q1 25 | $102.6M | $-151.1M | ||
| Q4 24 | $86.2M | $-133.2M | ||
| Q3 24 | $92.8M | $-133.5M | ||
| Q2 24 | $92.1M | $-131.6M | ||
| Q1 24 | $89.0M | $-170.7M |
| Q4 25 | 67.0% | -54.7% | ||
| Q3 25 | 69.2% | -106.9% | ||
| Q2 25 | 71.1% | -64.8% | ||
| Q1 25 | 75.8% | -102.6% | ||
| Q4 24 | 66.6% | -74.3% | ||
| Q3 24 | 71.8% | -94.6% | ||
| Q2 24 | 73.2% | -79.1% | ||
| Q1 24 | 73.3% | -151.9% |
| Q4 25 | 52.1% | -62.0% | ||
| Q3 25 | 53.7% | -112.8% | ||
| Q2 25 | 55.3% | -69.0% | ||
| Q1 25 | 59.2% | -108.5% | ||
| Q4 24 | 51.8% | -80.9% | ||
| Q3 24 | 55.9% | -95.7% | ||
| Q2 24 | 56.8% | -89.5% | ||
| Q1 24 | 57.0% | -156.8% |
| Q4 25 | $1.21 | $-1.28 | ||
| Q3 25 | $1.22 | $-1.81 | ||
| Q2 25 | $1.21 | $-1.17 | ||
| Q1 25 | $1.28 | $-1.57 | ||
| Q4 24 | $1.07 | $-1.34 | ||
| Q3 24 | $1.15 | $-1.40 | ||
| Q2 24 | $1.13 | $-1.52 | ||
| Q1 24 | $1.08 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.6B | $-80.0M |
| 总资产 | $3.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $2.6B | $-80.0M | ||
| Q3 25 | $2.5B | $9.2M | ||
| Q2 25 | $2.4B | $151.3M | ||
| Q1 25 | $2.3B | $144.2M | ||
| Q4 24 | $2.2B | $255.0M | ||
| Q3 24 | $2.2B | $346.8M | ||
| Q2 24 | $2.0B | $432.4M | ||
| Q1 24 | $2.0B | $140.3M |
| Q4 25 | $3.8B | $1.5B | ||
| Q3 25 | $3.7B | $1.2B | ||
| Q2 25 | $3.6B | $1.3B | ||
| Q1 25 | $3.5B | $1.3B | ||
| Q4 24 | $3.3B | $1.5B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.1B | $1.6B | ||
| Q1 24 | $3.0B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $419.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $412.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | 228.2% | -48.6% |
| 资本支出强度资本支出/营收 | 3.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.45× | — |
| 过去12个月自由现金流最近4个季度 | $764.9M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $419.3M | $-99.8M | ||
| Q3 25 | $128.0M | $-91.4M | ||
| Q2 25 | $128.4M | $-108.3M | ||
| Q1 25 | $101.2M | $-166.5M | ||
| Q4 24 | $393.6M | $-79.3M | ||
| Q3 24 | $128.4M | $-67.0M | ||
| Q2 24 | $117.8M | $-77.0M | ||
| Q1 24 | $111.6M | $-190.7M |
| Q4 25 | $412.5M | $-100.8M | ||
| Q3 25 | $126.3M | $-92.7M | ||
| Q2 25 | $126.7M | $-110.7M | ||
| Q1 25 | $99.4M | $-167.8M | ||
| Q4 24 | $386.7M | $-79.5M | ||
| Q3 24 | $126.9M | $-68.6M | ||
| Q2 24 | $115.9M | $-79.0M | ||
| Q1 24 | $109.4M | $-193.9M |
| Q4 25 | 228.2% | -48.6% | ||
| Q3 25 | 70.7% | -58.0% | ||
| Q2 25 | 72.9% | -66.5% | ||
| Q1 25 | 57.4% | -120.5% | ||
| Q4 24 | 232.2% | -48.3% | ||
| Q3 24 | 76.4% | -49.2% | ||
| Q2 24 | 71.5% | -53.7% | ||
| Q1 24 | 70.0% | -178.2% |
| Q4 25 | 3.8% | 0.5% | ||
| Q3 25 | 1.0% | 0.8% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.0% | 1.0% | ||
| Q4 24 | 4.1% | 0.1% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 1.1% | 1.4% | ||
| Q1 24 | 1.4% | 3.0% |
| Q4 25 | 4.45× | — | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | 0.99× | — | ||
| Q4 24 | 4.57× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 1.28× | — | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NMIH
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
